Vote Scores

Home / Companies / Intellia Therapeutics, Inc. / 9 Jun 2026

Meeting · year to 30 June 2026428 filers reporting

Intellia Therapeutics, Inc.: meeting of 9 Jun 2026

Votes reported on Form N-PX, item by item

428 Form N-PX filers reported votes at the Intellia Therapeutics, Inc. meeting of 9 Jun 2026. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

3 nominees; 65.6% of reported votes for; 60 filers withheld from or voted against at least one nominee.

651 vote records from 114 filers. 38 of the 112 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.

64.0% for34.2% against1.8% other33.9% against management114 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

599 vote records from 426 filers. 148 of the 397 filers that marked the item either way voted against management. 29 filers reported this item without a management mark.

57.5% for35.2% against7.3% other37.3% against management426 filers79.7% for20.3% against0.0% other20.3% against management64,432,755 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

217 vote records from 114 filers. 0 of the 112 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.

98.2% for0.0% against1.8% other0.0% against management114 filers100.0% for0.0% against0.0% against management28,231,995 reported shares

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForForFor
BlackRock and iSharesForForFor
FidelityForForFor
DimensionalAgainst *Against *For
State Street and SPDRForForFor
American CenturyAgainst *ForFor
InvescoForAgainst *For
EquitableForForFor
Charles SchwabForForFor
Nuveen and TIAAForForFor
ProShares and ProFundsAgainst *Against *For
John Hancock and ManulifeAgainst *Against *For
Morgan Stanley, Eaton Vance and CalvertAgainst *Against *For
J.P. MorganForForFor
Goldman SachsForForFor
WisdomTreeAgainst *ForFor
PGIM and PrudentialAgainst *Against *For
Jackson National fundsAgainst *Against *For
Northern Trust and FlexSharesForAgainst *For
SEIForForFor
T. Rowe PriceAgainst *Against *For
Lincoln FinancialForForFor
VoyaAgainst *ForFor
First TrustAgainst *Against *For
Russell InvestmentsForForFor
NationwideForForFor
Victory CapitalAgainst *Against *For
Brighthouse FundsForForFor
Guggenheim and RydexAgainst *Against *For
Columbia ThreadneedleForAgainst *For
BNY MellonNo reportForNo report
PrincipalAgainst *Against *For
Pacific Life fundsForForFor
Global XForForFor
MFSAgainst *ForFor
Federated HermesForForFor
AllianceBernsteinNo reportAgainst *No report
DWSAgainst *Against *For
AllspringAgainst *Against *For
MassMutualNo reportForNo report
Macquarie and Delaware FundsAgainst *Against *For
Neuberger BermanNo reportForNo report
American BeaconForForFor
Natixis and Loomis SaylesNo reportForNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Intellia Therapeutics, Inc. meeting?

428 Form N-PX filers reported votes at the meeting of 9 Jun 2026. On say-on-pay, 148 of 397 voted against management (37.3%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Intellia Therapeutics, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Intellia Therapeutics, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Intellia Therapeutics, Inc. with a meeting date within three days of 9 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.